Catalyst Calendar

Thu, Aug 6, 2026

1 updates

7:00 AM

Climb Bio Reports Second Quarter 2026 Financial Results and Provides Business Updates

CLYM116 Phase 1 data in healthy volunteers to be presented at R&D Spotlight Event on September 3, 2026 Anticipate CLYM116 Phase 2 trial in IgA nephropathy to initiate dosing in Q3 2026 Budoprutug clinical programs continue to advance, with data expected from pMN, ITP, and SLE studies in Q4 2026

Results Call • Phase 1Results call Thu, Sep 3, 2026climbbio.com

Thu, Jun 11, 2026

1 updates

CLYM

7:00 AM

Climb Bio Announces Initial Phase 1b Data Demonstrating On-Target Clinical Activity for Budoprutug in Immune Thrombocytopenia at EHA Congress 2026

Data demonstrate favorable safety and tolerability profile, robust B - cell depletion, and encouraging platelet responses in heavily pretreated patients with primary immune thrombocytopenia Enrollment ongoing in the high dose cohort, with additional data anticipated by year-end 2026 WELLESLEY

Presentation / Abstract • Phase 1EHA poster presentation Thu, Jun 11, 2026climbbio.com

Fri, Jun 5, 2026

1 updates

CLYM

7:00 AM

Climb Bio Presents CLYM116 Initial Phase 1 Safety Data and Translational Modeling Results at European Renal Association (ERA) Congress 2026 Supporting Continued Development

Company to share additional CLYM116 clinical data and plans for further development at R&D Spotlight in late summer Initiation of CLYM116 dosing in IgAN patients in Mabworks Phase 2 study expected in Q3 2026 WELLESLEY HILLS, Mass., June 05, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc.

Presentation / Abstract • Phase 1Oral presentation Fri, Jun 5, 2026, 3:03 PM BSTclimbbio.com